Prulifloxacin

Phase 3Small molecule

Merck & Co.

Prulifloxacin is one of 95 small molecule programs targeting Prostatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProstatitisActive, not recruiting

GastroenteritisActive, not recruiting

Chronic BronchitisActive, not recruiting

Urinary Tract InfectionActive, not recruiting

ProstatitisPhase 2

Active, not recruiting

GastroenteritisPhase 3

Active, not recruiting

Chronic BronchitisPhase 3

Active, not recruiting

Urinary Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

163 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 3

3 2

Medrol

Pfizer

Phase 3

1 3

Merrem

BB. Braun Medical Inc.

Phase 3

7 4

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

2 5

Decadron

AAspen Global Incorporated

Phase 3

1 6

Piperacillin/tazobactam

Pfizer

Phase 3

1 7

Amoxicillin/clavulanate Potassium

Johnson & Johnson

Phase 3

1 8

Prulifloxacin

Merck & Co.

Phase 3

1 9

Blujepa

GGlaxo Dba Glaxosmithkline

Phase 3

5 10

Imipenem+cilastatin/relebactam

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Bronchitis1 trial

A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control

Unknown status·LLee's Pharmaceutical Limited·Phase 3·NCT02157571·360 enrolled

Efficacy1 trial

Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)

Unknown status·UUniversity Of Perugia·Phase 2·NCT01231737·96 enrolled

Diarrhea1 trial

Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00392574·282 enrolled

Gastroenteritis1 trial

Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00448422·268 enrolled

Urinary Tract Infection1 trial

A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control

Completed·LLee's Pharmaceutical Limited·Phase 3·NCT02439632·216 enrolled

1 more indication

Prostatitis1 trial

Prulifloxacin in Chronic Bacterial Prostatitis (CBP)

Completed·AAziende Chimiche Riunite Angelini Francesco S.p.A·Phase 2·NCT03201796·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Prulifloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prulifloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prulifloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Prulifloxacin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Bronchitis1 trial

Efficacy1 trial

Diarrhea1 trial

Gastroenteritis1 trial

Urinary Tract Infection1 trial

Prostatitis1 trial

References

Drug Info

Quick Facts

Related News